Scholarlink

<p>Lower urinary tract symptoms (LUTS; i.e. storage, voiding and post-micturition symptoms) are a frequent complaint in adult men and strongly associated with aging. A common cause is benign prostatic obstruction, which typically results from benign prostatic hyperplasia (BPH) progressing through benign prostatic enlargement. Treatment of BPH-associated LUTS can be conservative, pharmacological or surgical, and aims to reduce the obstruction and alleviate LUTS. A personalized approach (considering, among other factors, symptom severity, prostate size, comorbidities and patient preference) is recommended. In patients with mixed symptom profiles or those who have insufficiently responded to pharmacological monotherapy, the use of pharmacological combination therapy (e.g. α1-adrenoceptor antagonist plus 5-alpha reductase inhibitor) may be warranted. Tolerability data for most pharmacological combination therapies are limited.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Manage benign prostatic hyperplasia-associated lower urinary tract symptoms using a personalized approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Sheridan M. Hoy

摘要

Lower urinary tract symptoms (LUTS; i.e. storage, voiding and post-micturition symptoms) are a frequent complaint in adult men and strongly associated with aging. A common cause is benign prostatic obstruction, which typically results from benign prostatic hyperplasia (BPH) progressing through benign prostatic enlargement. Treatment of BPH-associated LUTS can be conservative, pharmacological or surgical, and aims to reduce the obstruction and alleviate LUTS. A personalized approach (considering, among other factors, symptom severity, prostate size, comorbidities and patient preference) is recommended. In patients with mixed symptom profiles or those who have insufficiently responded to pharmacological monotherapy, the use of pharmacological combination therapy (e.g. α1-adrenoceptor antagonist plus 5-alpha reductase inhibitor) may be warranted. Tolerability data for most pharmacological combination therapies are limited.